Trial Profile

Phase 3 pivotal trial assessing CTC-501 for the treatment of Major Depressive Disorder (MDD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pramipexole (Primary)
Indications Major depressive disorder
Focus Registrational; Therapeutic Use
Sponsors Chase Therapeutics

Most Recent Events

27 Oct 2021 New trial record
20 Oct 2021 According to Chase Therapeutics media release, the completion of a milestone based $20M Series B financing led by Chinalink Asia Holdings of Hong Kong will support this trial

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com